ArticleAmerican journal of cancer research2024

Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation.

Vida Tajiknia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.